Indivior Pharmaceuticals Inc (INDV) P/E Ratio History
UndervaluedTrading at 25.5x vs 5Y avg 78.8x · 50th percentile · Below historical baseline · Data 2022–2026
Loading P/E history...
P/E Ratio Analysis
As of June 29, 2026, Indivior Pharmaceuticals Inc (INDV) trades at a price-to-earnings ratio of 25.5x, with a stock price of $41.83 and trailing twelve-month earnings per share of $1.95.
The current P/E is 68% below its 5-year average of 78.8x. Over the past five years, INDV's P/E has ranged from a low of 13.4x to a high of 381.8x, placing the current valuation at the 50th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, INDV is roughly in line with its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, INDV trades roughly in line with the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our INDV DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
INDV Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
INDV P/E vs Peers
Therapy-focused branded biopharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $386M | 10.0Lowest | - | +171% | |
| $2B | 72.6 | - | +194% | |
| $9B | 38.5 | - | -34% | |
| $2B | 11.1 | - | +431%Best | |
| $1B | 21.2 | 1.18Best | -7% | |
| $418M | 47.7 | - | -43% | |
| $993M | 157.8 | - | +107% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
INDV Historical P/E Data (2022–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $30.48 | $1.98 | 15.4x | -80% |
| FY2025 Q4 | Dec 31 2025 | $35.88 | $1.67 | 21.5x | -73% |
| FY2025 Q3 | - | $24.11 | $1.30 | 18.5x | -76% |
| FY2025 Q2 | Jun 30 2025 | $14.74 | $1.00 | 14.7x | -81% |
| FY2025 Q1 | Mar 31 2025 | $9.53 | $0.14 | 68.1x | -14% |
| FY2024 Q4 | - | $12.43 | $0.21 | 59.2x | -25% |
| FY2024 Q3 | Sep 30 2024 | $9.75 | $0.14 | 69.6x | -12% |
| FY2024 Q1 | Mar 31 2024 | $21.42 | $0.17 | 126.0x | +60% |
| FY2023 Q4 | Dec 31 2023 | $15.27 | $0.04 | 381.8x | +384% |
| FY2022 Q3 | Sep 30 2022 | $15.00 | $1.12 | 13.4x | -83% |
Average P/E for displayed period: 78.8x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
INDV — Frequently Asked Questions
Quick answers to the most common questions about buying INDV stock.
What is INDV's P/E ratio?
Indivior Pharmaceuticals Inc (INDV) trailing twelve-month P/E ratio is 25.5x, based on TTM diluted EPS of $1.95. The 5-year average P/E is 78.8x and the historical range spans 13.4x to 381.8x.
Is INDV stock overvalued or undervalued?
INDV trades at 25.5x P/E, below its 5-year average of 78.8x. At the 50th percentile of its historical range (13.4x–381.8x), the stock is priced at a discount to its own history.
Is INDV stock expensive?
No, INDV is not expensive on a historical basis. The current P/E of 25.5x is below the 5-year average of 78.8x and sits at the 50th percentile of its valuation range.
What is INDV's historical P/E range?
Over the past 5 years, INDV's P/E ratio has ranged from 13.4x to 381.8x, with a median of 59.2x and an average of 78.8x. The current P/E of 25.5x places the stock at the 50th percentile of this range. Full historical data spans 2022–2026.
How does INDV's P/E compare to the S&P 500?
INDV trades at 25.5x P/E versus the S&P 500 median of 25.3x. The 1% premium to the market typically reflects higher expected earnings growth or quality.
How does INDV's valuation compare to Healthcare peers?
Indivior Pharmaceuticals Inc P/E of 25.5x compares to the Healthcare sector median of 23.0x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is INDV's PEG ratio?
INDV PEG ratio is N/A, based on a P/E of 25.5x and EPS growth of 10833.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is INDV's earnings yield?
INDV earnings yield is 3.92%, the inverse of its 25.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.